Drugs in Dev. Dermatology
Phase I
Taiwan 
Lead Product(s) : AH 001
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AnHorn Doses First Patient in AH-001 Phase I Trial in U.S.
Details : AH-001 is a first-in-class protein degrader, which is currrently being evaluated for the treatment of androgenetic alopecia.
Product Name : AH-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : AH 001
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TWiB Receives Canada Health Approval for AC-1101 Phase 1 CTA
Details : Health Canada has approved Ancheng Biotech's open-label, fixed-sequence, two-period, comparative bioavailability study of AC-1101 (Tofacitinib Citrate). Tofacitinib Citrate is a topical JAK inhibitor for the treatment of vitiligo.
Product Name : AC-1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2020
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
